![Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study - The Lancet Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study - The Lancet](https://www.thelancet.com/cms/attachment/a3e48024-327b-4760-9da1-13676e339e37/gr1_lrg.jpg)
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study - The Lancet
![Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials - The Lancet Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials - The Lancet](https://www.thelancet.com/cms/attachment/db5c63dc-ee49-4b78-b05c-e93ffa8229af/gr1_lrg.jpg)
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials - The Lancet
![Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR](https://www.cdc.gov/mmwr/volumes/71/wr/social-media/mm7148e1-BivalentBooster_IMAGE_22NOV2022_1200x675.jpg?_=65732)
Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR
![Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years | Nature Medicine Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-022-01832-0/MediaObjects/41591_2022_1832_Fig1_HTML.png)
Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years | Nature Medicine
![BioNTech SE on X: "95.6% relative vaccine efficacy against #Covid19 after a booster shot with our #mRNA vaccine, during a period when Delta was the prevalent strain. These are the first efficacy BioNTech SE on X: "95.6% relative vaccine efficacy against #Covid19 after a booster shot with our #mRNA vaccine, during a period when Delta was the prevalent strain. These are the first efficacy](https://pbs.twimg.com/media/FCN6ON9X0AE9wnO.jpg)
BioNTech SE on X: "95.6% relative vaccine efficacy against #Covid19 after a booster shot with our #mRNA vaccine, during a period when Delta was the prevalent strain. These are the first efficacy
![Boosters wane but showed protection against hospitalization during omicron, CDC study says - The Washington Post Boosters wane but showed protection against hospitalization during omicron, CDC study says - The Washington Post](https://datawrapper.dwcdn.net/cvun1/fallback.png)
Boosters wane but showed protection against hospitalization during omicron, CDC study says - The Washington Post
![Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design - The Lancet Infectious Diseases Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design - The Lancet Infectious Diseases](https://www.thelancet.com/cms/asset/91d19b8e-2f0b-4e13-8d9b-69e012d37e25/gr1.jpg)
Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design - The Lancet Infectious Diseases
![Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study - The Lancet Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study - The Lancet](https://www.thelancet.com/cms/attachment/97d1c5ff-af79-4d10-b5b8-3026a35a572d/gr1_lrg.jpg)
Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study - The Lancet
![Rollout Strategy for the Pfizer-BioNTech COVID-19 Vaccine in Ontario - Ontario COVID-19 Science Advisory Table Rollout Strategy for the Pfizer-BioNTech COVID-19 Vaccine in Ontario - Ontario COVID-19 Science Advisory Table](https://covid19-sciencetable.ca/wp-content/uploads/2020/12/Figure-1.jpg)
Rollout Strategy for the Pfizer-BioNTech COVID-19 Vaccine in Ontario - Ontario COVID-19 Science Advisory Table
![Vaccines | Free Full-Text | The Four Ws of the Fourth Dose COVID-19 Vaccines: Why, Who, When and What Vaccines | Free Full-Text | The Four Ws of the Fourth Dose COVID-19 Vaccines: Why, Who, When and What](https://www.mdpi.com/vaccines/vaccines-10-01924/article_deploy/html/images/vaccines-10-01924-g001.png)